HOUSTON–(BUSINESS WIRE)–Oceanit, the energy and climate innovator, announces the launch of its EDGE (Energy & Decarbonization for the Global Environment) in-house incubator, coinciding with OTC2022. Energy efficiency, hydrogen tech, and decarboni… […]
PALO ALTO, Calif., April 29, 2022 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other ser… […]
SOUTH SAN FRANCISCO, Calif., April 29, 2022 /PRNewswire/ — Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineerin… […]
Faculty reflect on 50 years of artificial intelligence advances and discuss what the future holds for this technology. […]
DAVIS, Calif., April 29, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a science-based, data-driven regenerative aesthetic skincare company is pleased to announce the appointment of industry expert Brenda Buechler as Chief Marketi… […]
Nascar driver extends community and charitable contributions with heartwarming experiences for sick or injured children and their families SAN JOSE, Calif and CONCORD, N.C., April 29, 2022 /PRNewswire/ — Earlier today, Nascar Xfinity Series driver Jos… […]
Gilead’s two cents: Drugmaker gets a boost from Biktarvy, Veklury but $2.7B writedown crushes earnings
zbecker
Fri, 04/29/2022 – 08:03
SAN FRANCISCO, April 29, 2022 /PRNewswire/ — Quantum Leap Healthcare Collaborative™ (QLHC) announces the award of OneSource, Quantum Leap Healthcare Collaborative’s groundbreaking clinical trial data management solution developed in collaboration with… […]
SAN JOSE, Calif.–(BUSINESS WIRE)– #AdvancedManufacturing–Boeing teams up with NextFlex® to expand FlexFactor® and Flex2Future® workforce development programs. […]
Gilead got a sales boost from its Covid-19 treatment for the first quarter — to the tune of $1.5 billion. The likely temporary bump came just in time though as Gilead reassessed its cancer drug Trodelvy’s value and took a $2.7 billion R&D impairmen… […]
Copyright © 2022 Biotech Networks, LLC
